These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31062991)

  • 1. An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy.
    Galvano A; Guarini A; Iacono F; Castiglia M; Rizzo S; Tarantini L; Gori S; Novo G; Bazan V; Russo A
    Expert Opin Drug Saf; 2019 Jun; 18(6):485-496. PubMed ID: 31062991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.
    Bronte G; Bronte E; Novo G; Pernice G; Lo Vullo F; Musso E; Bronte F; Gulotta E; Rizzo S; Rolfo C; Silvestris N; Bazan V; Novo S; Russo A
    Expert Opin Drug Saf; 2015 Feb; 14(2):253-67. PubMed ID: 25494575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.
    Dobbin SJH; Cameron AC; Petrie MC; Jones RJ; Touyz RM; Lang NN
    Heart; 2018 Dec; 104(24):1995-2002. PubMed ID: 30228246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
    Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
    Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
    Eskens FA; Verweij J
    Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia P; Morgan CJ; Je Y; Nguyen PL; Trinh QD; Choueiri TK; Sonpavde G
    Crit Rev Oncol Hematol; 2015 May; 94(2):228-37. PubMed ID: 25577572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity.
    O'Hare M; Murphy K; Mookadam F; Sharma A; Lee H
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):519-27. PubMed ID: 25864865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies.
    Ekram J; Rathore A; Avila C; Hussein R; Alomar M
    Cancer Control; 2024; 31():10732748241285755. PubMed ID: 39318033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib malate for the treatment of renal cell carcinoma.
    Wood L
    Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management.
    Jiang L; Ping L; Yan H; Yang X; He Q; Xu Z; Luo P
    Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):823-835. PubMed ID: 32597258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncologic therapies associated with cardiac toxicities: how to minimize the risks.
    Cardinale D; Stivala F; Cipolla CM
    Expert Rev Anticancer Ther; 2019 May; 19(5):359-374. PubMed ID: 30916598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity.
    Scott SS; Greenlee AN; Matzko A; Stein M; Naughton MT; Zaramo TZ; Schwendeman EJ; Mohammad SJ; Diallo M; Revan R; Shimmin G; Tarun S; Ferrall J; Ho TH; Smith SA
    Heart Fail Clin; 2022 Jul; 18(3):425-442. PubMed ID: 35718417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
    Furuya-Kanamori L; Doi SA; Onitilo A; Akhtar S
    Expert Opin Drug Saf; 2020 Feb; 19(2):223-228. PubMed ID: 31698959
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardio-oncology: management of cardiovascular toxicity.
    Markman TM; Markman M
    F1000Res; 2019; 8():. PubMed ID: 30755794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors.
    De Luca A; Normanno N
    IDrugs; 2010 Sep; 13(9):636-45. PubMed ID: 20799147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia P; Morgan CJ; Choueiri TK; Rocha P; Naik G; Sonpavde G
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):136-45. PubMed ID: 25541349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
    Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
    Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.
    Liu J; Nicum S; Reichardt P; Croitoru K; Illek B; Schmidinger M; Rogers C; Whalen C; Jayson GC
    Gynecol Oncol; 2018 Jul; 150(1):173-179. PubMed ID: 29627080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management.
    Vallerio P; Orenti A; Tosi F; Maistrello M; Palazzini M; Cingarlini S; Colombo P; Bertuzzi M; Spina F; Amatu A; Lombardo R; Prata I; Scaglione F; Vighi GD; Severgnini B; Siena S; Giannattasio C; Boracchi P; Sartore-Bianchi A
    ESMO Open; 2022 Feb; 7(1):100338. PubMed ID: 34920290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal Cancer Therapy and Cardiotoxicity.
    Leiva O; Zarif TE; Alvarez-Cardona J
    Curr Treat Options Oncol; 2024 Sep; 25(9):1203-1209. PubMed ID: 39102169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.